BICO has been awarded this year's SwedenBIO Award for showcasing the power of the Swedish life-science industry on the global arena and its visionary business model and remarkable growth
The world-leading bio convergence company, BICO, today announced that it has received SwedenBIO's Award which was announced in connection with SwedenBIO's Annual Summit in
"We are incredibly honored to receive this award from SwedenBIO, an important and respected industry player," says Erik Gatenholm, CEO and co-founder of BICO. "I am humbled and look forward to continue to develop our offering and contribute to enabling Health 4.0."
SwedenBIO is one of
"BICO has contributed to the good repute of the Swedish life-science industry internationally and shown what can be achieved with a bold approach to market expansion. By presenting them with the SwedenBIO Award, we hope that BICO can inspire Swedish companies as they strive to take market shares in their respective areas," said
The SwedenBIO Award is the industry's own award and is awarded in collaboration with HealthCap. Presented each year since 2007 it includes the distinction of the award, a floating trophy that changes hands annually with each new champion, and attendance at Nordic Life Science Days in Malmö in
Founded in 2016, BICO has quickly grown from being one company focused on bioinks and bioprinters to a global cohesive group of thirteen companies with an extensive range of bio convergence products and solutions enabling Health 4.0. BICO focuses on four Next Generation Core industrial eco systems; Tissue Engineering, Diagnostics, Multiomics and
For more information on SwedenBIO, please visit: www.swedenbio.se
For further information, please contact:
Hedda Söderström, Communications Manager: + 46 73 509 2261
Email: press@bico.com
Riley Munks, PR Manager: (650) 863-6699
Alyssa D'Orazio, PR Manager: (617) 634-9601
Email: press@bico.com
This information was submitted for publication, through the agency of the contact persons set out above, on
About BICO
Founded in 2016, BICO (formerly
The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO's technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group's instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com
https://news.cision.com/bico-group/r/bico-wins-swedenbio-award-2021,c3468004
https://mb.cision.com/Main/14960/3468004/1507081.pdf
(c) 2021 Cision. All rights reserved., source